Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$343.49M+85.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Patrick J. Beyer
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 3,900
- Beta
- 0.91
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.92
Financials
Revenue
$343.49M+85.9%Net Income
$23.07M+214.4%EBITDA
$61.28M+120.7%Free Cash Flow
$34.16M+55.3%EPS (diluted)
$0.77+196.2%Shares Outstanding (diluted)
30.12M+7.7%Operating Expenses
$161.05MCash & Debt
$37.33MReturn of Capital
$6.20MRevenue by Segment (annual)
$1.37BDividend per Share
$0.20Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.37B | $47.05M | $1.52 |
| 2024 | $1.31B | $132.42M | $4.29 |
| 2023 | $1.24B | $64.46M | $2.10 |
| 2022 | $1.05B | $-80.58M | $-2.68 |
| 2021 | $1.01B | $62.54M | $2.14 |
| 2020 | $862.46M | $9.52M | $0.33 |
| 2019 | $955.10M | $28.62M | $1.01 |
| 2018 | $859.63M | $40.85M | $1.45 |
| 2017 | $796.39M | $55.49M | $1.99 |
| 2016 | $763.52M | $14.66M | $0.53 |
| 2015 | $719.17M | $30.50M | $1.10 |
| 2014 | $734.47M | $32.19M | $1.17 |
| 2013 | $756.75M | $35.94M | $1.30 |
| 2012 | $767.14M | $40.48M | $1.43 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CNMD's reported EPS growth of 0.5% a year over 13 years.
- EPS in 5 years
- $1.55
- Implied price
- $41.97
- Return from $46.69
- -2.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $20.87 — -55.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 19 | 23 | 27 | 31 | 35 |
|---|---|---|---|---|---|
| -9.5% | -17.8% | -14.6% | -11.8% | -9.4% | -7.2% |
| -4.5% | -13.3% | -9.9% | -7.0% | -4.4% | -2.0% |
| 0.5% | -8.8% | -5.2% | -2.1% | 0.6% | 3.1% |
| 5.5% | -4.2% | -0.5% | 2.8% | 5.6% | 8.2% |
| 10.5% | 0.3% | 4.2% | 7.6% | 10.6% | 13.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-62.89%Social Signal Score
Mentions (7)
- Newszacks.com·19d ago·Positive
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
View source ↗ - Newszacks.com·38d ago·Neutral
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue? Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·48d ago·Positive
CONMED Corporation: Organic Growth Is Masked By Divestitures Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highl
View source ↗ - Newszacks.com·49d ago·Positive
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
View source ↗ - Newszacks.com·49d ago·Positive
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum? CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
View source ↗ - Newszacks.com·49d ago·Neutral
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk? CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
View source ↗ - Newszacks.com·49d ago·Neutral
Here's Why You Should Retain CONMED Stock in Your Portfolio Now CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $1.00 per share
Typical surprise +8.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.38 vs $1.11beat
- Wed, Apr 29$0.89 vs $0.82beat
- Wed, Jan 28$1.43 vs $1.32beat
- Wed, Nov 5$1.08 vs $1.05beat
- Wed, Jul 30$1.15 vs $1.13beat
- Wed, Apr 30$0.95 vs $0.81beat
Estimates and results for CNMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNMD officers and directors.
- Bought
- —
- Sold
- $300k
0 trades
5 trades
- Glaze Richardsold
- Garner Todd Wsold
- Farkas Charlessold
- Farkas Charlessold
- Garner Todd Wsold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$1,001 - $15,000
- Van Taylorhouse · TX03 · disclosed Mar 14, 2019 (27d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.